Yabao Pharmaceutical: Termination of SY-009 clinical trial and provision for impairment will reduce the total profit of 2025 by 55.7933 million yuan
2025-09-22 08:06:27
On September 22nd, Yabao Pharmaceutical announced that the company decided to terminate the clinical research and development of SY-009 and make a full provision for asset impairment according to accounting standards. SY-009 is a sodium-glucose cotransporter 1 inhibitor, which is intended for the treatment of type 2 diabetes patients. As of the announcement date, the R & D investment of SY-009 totaled 87.8698 million yuan, of which the expensed amount was 32.0765 million yuan and the capitalized amount was 55.7933 million yuan. The provision for asset impairment will reduce the company's total profit in 2025 by 55.7933 million yuan.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
